欢迎访问《中国临床药理学与治疗学》杂志官方网站,今天是

中国临床药理学与治疗学 ›› 2024, Vol. 29 ›› Issue (11): 1212-1219.doi: 10.12092/j.issn.1009-2501.2024.11.002

• 基础研究 • 上一篇    下一篇

头孢哌酮舒巴坦对胆汁引流大鼠华法林药代动力学和药效动力学的影响

陈阳1,王欣怡1,李波霞1,2,卫治理1,宋兵1,3   

  1. 1兰州大学第一临床医学院,兰州  730000,甘肃;2兰州大学第一医院药剂科,兰州  730000,甘肃;3兰州大学第一医院心血管外科,兰州  730000,甘肃

  • 收稿日期:2023-12-13 修回日期:2024-01-24 出版日期:2024-11-26 发布日期:2024-10-24
  • 通讯作者: 宋兵,男,硕士生导师,主任医师,研究方向:心血管外科。 E-mail: songbinldyy@163.com
  • 作者简介:陈阳,男,在读硕士,研究方向:胸心外科。 E-mail: cy445423553@163.com
  • 基金资助:
    国家自然科学基金(82260729);中国药学会医院药学专委会科研专项(CPA-Z05-ZC-2022-002);兰州大学第一医院院内基金(ldyyyn2021-113);兰州大学学生创新创业项目(202310730190)

Effects of cefoperazone-sulbactam on the pharmacokinetics and pharmacodynamics of warfarin in rats

CHEN Yang1, WANG Xinyi1, LI Boxia1,2, WEI Zhili1, SONG Bing1,3   

  1. 1The First Clinical Medical College of Lanzhou University, Lanzhou 730000, Gansu, China; 2Department of Pharmacy, the First Hospital of Lanzhou University, Lanzhou 730000, Gansu, China; 3Department of Cardiovascular Surgery, First Hospital of Lanzhou University, Lanzhou 730000, Gansu, China
  • Received:2023-12-13 Revised:2024-01-24 Online:2024-11-26 Published:2024-10-24

摘要:

目的:探讨头孢哌酮舒巴坦对华法林药代动力学和药效动力学的影响及其对华法林药效增强作用的机制。方法:将大鼠随机分为4组,WN组:单用华法林健康大鼠组;WCN组:华法林联用头孢哌酮舒巴坦健康大鼠组;WO组:胆道引流术后单用华法林组;WCO:胆道引流术后华法林联用头孢哌酮舒巴坦大鼠组。测定不同时间点华法林血药浓度,同时尾静脉采血测定国际标准化比值(INR)。采用非房室模型计算药代动力学参数。Western blotting测定WN组和WCN组回肠组织中P-糖蛋白(P-gp)的表达水平。结果:与WN组比较,WCN组的AUC0-t、Cmax和Ka显著增加,CL/F显著减少,INR值明显增加,而WO组与WCO组药代动力学参数及INR值无统计学差异。WO组的AUC0-t、Cmax相较于WN组显著降低,t1/2显著延长。WCO组的AUC0-t、Cmax相较于WCN组亦显著降低,t1/2显著延长。WCN组在6 h后的INR显著高于WCO组。Western blotting结果显示WCN组回肠P-gp的表达水平较WN组降低了62.1%(P<0.01)。结论:头孢哌酮舒巴坦可通过抑制肠道P-gp表达显著影响华法林的药代动力学,并增强其药效;胆汁引流显著影响华法林大鼠药代动力学,胆汁引流后二者无明显药物相互作用。

关键词: 华法林, 药代动力学, 头孢哌酮舒巴坦, 药效动力学, 胆道引流

Abstract:

AIM: To elucidate the effects of cefoperazone-sulbactam on the pharmacokinetics of warfarin and the mechanism behind the enhancement of warfarin's efficacy. METHODS: Thirty-two rats were randomly assigned to four groups: WN (healthy rats after the gastric-administration of 0.125 mg/kg warfarin), WCN (healthy rats after the gastric-administration of 0.125 mg/kg warfarin and 0.3 g/kg cefoperazone-sulbactam), WO (a rat model of biliary drainage after the gastric-administration of 0.125 mg/kg warfarin), WCO (a rat model of biliary drainage after the gastric-administration of 0.125 mg/kg warfarin and 0.3 g/kg cefoperazone-sulbactam). Blood samples were collected at various time points from the femoral artery to determine the plasma concentration of warfarin and from the tail vein to measure the International Normalized Ratio (INR). Warfarin levels were quantified using LC/MS/MS, and pharmacokinetic parameters were calculated using a non-compartmental model. The expression of P-glycoprotein (P-gp) in the ileal tissues of the WN and WCN groups was determined by Western blotting. RESULTS: Compared with the WN group, the WCN group demonstrated a significant increase in AUC0-t, Cmax, and Ka, and a notable decrease in CL/F, and INR values significantly increased. However, there was no significant difference in pharmacokinetic parameters and INR values between the WO group and the WCO group. Compared to the WN group, the WO group showed a significant reduction in AUC0-t, Cmax, and CL/F, with an obvious increase in t1/2. The INR of the WCN group was significantly higher than that of the WCO group after 6 hours.Western blotting results indicated a 62.1% reduction in P-gp expression in the ileum of the WCN group compared to the WN group (P<0.01). CONCLUSION: Cefoperazone-sulbactam significantly influences the pharmacokinetic parameters of warfarin and enhances its pharmacological effect by inhibiting intestinal P-gp expression. Biliary drainage significantly affects the pharmacokinetics of warfarin rats, and there is no significant drug interaction between the two after biliary drainage.

Key words: warfarin, pharmacokinetics, cefoperazone-sulbactam, pharmacodynamics, biliary rainage

中图分类号: